The social costs of digital ulcer management in sclerodema patients: An observational Italian pilot study

Joint Bone Spine

Volumn 77, Issue 1, 2010, Pages 83-84

  Cozzi, Franco ^a   Tiso, Francesco ^a   Lopatriello, Stefania ^b   Ciprian, Luca ^a   Sfriso, Paolo ^a   Berto, Patrizia ^b   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Pbe Consulting   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PROSTAGLANDIN E1;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITAL ULCER; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; ITALY; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PATIENT CARE; PILOT STUDY; REIMBURSEMENT; SCLERODERMA; SYSTEMIC SCLEROSIS; ULCER; ULCER HEALING;

FEMALE; FINGERS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; ILOPROST; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN ULCER; SOCIAL RESPONSIBILITY; VASODILATOR AGENTS;

EID: 73449136308     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.05.015     Document Type: Letter

References (10)

1. Korn J.H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993
2. Ferri C., Valentini G., Cozzi F., et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 81 (2002) 139-153 Review
3. Wigley F.M., Wise R.A., Seibold J.R., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120 (1994) 199-206
4. Bettoni L., Geri A., Airò P., et al. Systemic sclerosis therapy with iloprost: A prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21 (2002) 244-250
5. Allanore Y., Avouac J., and Kahan A. Systemic sclerosis: An update in 2008. Joint Bone Spine 75 (2008) 650-655
6. Avouac J., Kowal-Bielecka O., Landewè R.B.M., et al. EULAR sclerodermia trial and research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research. Ann Rheum Dis 68 (2009) 629-634
7. Wilson L. Cost-of-illness of scleroderma: The case for rare diseases. Semin Arthritis Rheum 27 (1997) 73-84
8. Nietert P.J., Silverstein M.D., and Silver R.M. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 28 (2001) 2031-2037
9. Belotti Masserini A., Zeni S., Cossutta R., et al. Cost-of-illness in systemic sclerosis: A retrospective study of an Italian cohort of 106 patients. Reumatismo 55 (2003) 245-255
10. Nihtyanova S.I., Brough G.M., Black C.M., et al. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67 (2008) 120-123